New drug cocktail aims to wipe out stomach cancer before surgery
NCT ID NCT07477444
First seen Mar 19, 2026 · Last updated May 23, 2026 · Updated 7 times
Summary
This early-phase trial tests whether adding two targeted drugs (zanidatamab and tislelizumab) to standard chemotherapy can completely eliminate HER2-positive gastroesophageal cancer before surgery. About 29 adults with operable, locally advanced cancer will receive the combination before and after tumor removal. The main goals are safety and seeing how many patients have no cancer left at surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROESOPHAGEAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.